Towards Healthcare
Cell and Gene Therapy CRO Market to Reach USD 12.59 Bn by 2034

Cell and Gene Therapy CRO Market Trends Shaping 2025 Future

Projections indicate that, cell and gene therapy CRO industry is projected to rise from USD 4.90 billion in 2024 to USD 12.59 billion by 2034, reflecting a CAGR of 9.9% over the next decade. The cell and gene therapy CRO market is growing as CROs work with cell and gene therapies targeting a wide array of diseases, cancer, rare and inherited genetic disorders, neurodegenerative and degenerative diseases, and immunological and infectious diseases. North America is dominant in the market due strong biotechnology ecosystem and robust funding from the government.

Content

  • Insight Code: 6095
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The cell and gene therapy CRO market is valued at USD 5.39 billion in 2025 and is on track to reach USD 12.59 billion by 2034, witnessing a steady CAGR of 9.9% during the forecast span.

North America is currently leading the cell and gene therapy CRO market due to its high healthcare expenditure and increasing demand for personalized medicine.

Some key players include Charles River Laboratories, Labcorp / Covance, ICON plc, IQVIA, Parexel, Syneos Health, and Medpace.

502 cell and gene therapy companies worldwide.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions